Navigation Links
Andrew P. Mandell - Mr. Diabetes(R) to Sit On ProtoKinetix Advisory Board

MADEIRA BEACH, Fla., Jan. 15 /PRNewswire/ -- Andrew P. Mandell – Mr. Diabetes®, Executive Director of Defeat Diabetes Foundation and diabetes advocate announced today that he will be sitting on the ProtoKinetix (PKTX) Advisory Board.  ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP™) for medicine and the biotechnology and cosmetic industries.

"I'm really excited about their technology and it's potential to offer the first truly viable long term treatment for diabetes," said Mandell. "The Protokinetix's research team has made remarkable progress in the harvesting and preservation of stem cells for islet transplantation for diabetes treatments," he continued.

"In addition to the potential treatments for diabetes, AAGP™ also shows great promise in many other medical applications. I'm really looking forward to contributing where I can to support their work," Mandell concluded.

Defeat Diabetes Foundation

Defeat Diabetes Foundation is a 501(c)(3) nonprofit  whose mission is the prevention, early identification and effective self management of diabetes.

DDF has awareness and interactive programs in all 50 states to provide critical information and education programs with a focus on diabetes, nutrition and physical fitness. Their public information programs include the KIDD™ Project which has provided millions of Free Defeat Diabetes® Screening Test brochures to schools in all 50 states, the DAN Project, a Public Service Announcements program and the Martial Arts Defeat Diabetes® Community Action Project (MADDCAP™) a historic health curriculum for martial arts schools and their students.

For information on diabetes, to take the free screening test or obtain additional information visit:

For information on ProtoKinetix visit the website at:

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

SOURCE Defeat Diabetes Foundation



SOURCE Defeat Diabetes Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vical Names Andrew de Guttadauro Vice President, Corporate Development
2. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
3. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
4. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Algeta Appoints Andrew Kay as President and Chief Executive Officer
7. Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
8. Veridiam Appoints Andrew Gale as Chief Executive Officer
9. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
10. Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club
11. ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... International Society for Pharmaceutical Engineering (ISPE) ... annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in ... largest number of attendees in more than a decade. , “The 2015 ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Financial Officer, will participate in the Piper Jaffray 27 th ... NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
Breaking Biology Technology:
(Date:11/19/2015)...  Although some 350 companies are actively involved in ... companies, according to Kalorama Information. These include Roche Diagnostics, Hologic, ... share of the 6.1 billion-dollar molecular testing market, according ... Molecular Diagnostic s .    ... by one company and only a handful of companies ...
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):